metoprolol has been researched along with Disease Models, Animal in 119 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoprolol is regarded as a first-line medicine for the treatment of myocardial infarction (MI)." | 7.96 | Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats. ( Li, Z; Qin, W; Xiao, D; Xu, C; Yang, H; Zhang, H; Zhang, L; Zhang, Y, 2020) |
| "We examined whether intratracheal delivery of metoprolol can reduce ventricular rate during atrial fibrillation (AF) and accelerate conversion to sinus rhythm." | 7.96 | Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Marum, AA; Medeiros, SA; Nearing, BD; Pedreira, GC; Tessarolo Silva, F; Verrier, RL, 2020) |
| "Metoprolol (Met) is widely applied in the treatment of myocardial infarction and coronary heart disease in clinic." | 7.96 | Metabolomic profiling of metoprolol-induced cardioprotection in a murine model of acute myocardial ischemia. ( Kou, J; Lai, Q; Li, F; Liu, Z; Wang, H; Yu, B; Yuan, G, 2020) |
| "Cerebral ischemia has previously been shown to cause a systemic decrease in levels of the reduced forms of low-molecular-weight aminothiols [cysteine (Cys), homocysteine (Hcy), and glutathione (GSH)] in blood plasma." | 7.88 | Metoprolol and Nebivolol Prevent the Decline of the Redox Status of Low-Molecular-Weight Aminothiols in Blood Plasma of Rats During Acute Cerebral Ischemia. ( Alexandrin, VV; Bulgakova, PO; Ivanov, AV; Kubatiev, AA; Nikiforova, KA; Paltsyn, AA; Sviridkina, NB; Virus, ED, 2018) |
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 7.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| "Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA." | 7.81 | Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015) |
| "Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment." | 7.80 | Sorafenib cardiotoxicity increases mortality after myocardial infarction. ( Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D, 2014) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 7.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 7.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 7.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "Rabbit heart failure model was established by aortic insufficiency induced volume overload followed 14 days later by pressure overload induced by abdominal aorta constricting (HF, n = 11), another 8 rabbits with heart failure were treated with metoprolol (ME) for 6 weeks, sham-operated rabbits (n = 11) served as control." | 7.74 | [Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure]. ( Han, LH; Jiang, B; Jiang, TB; Jiang, WP; Li, BY; Li, HX; Liu, ZH; Song, JP; Yang, XJ; Zou, C, 2007) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 7.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 7.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 7.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death in patients with myocardial infarction (MI)." | 5.48 | Comparison between renal denervation and metoprolol on the susceptibility of ventricular arrhythmias in rats with myocardial infarction. ( Chen, C; Geng, J; Huo, J; Jiang, W; Jiang, Z; Lu, D; Shan, Q; Xu, H, 2018) |
| "Metoprolol (Met) is widely applied in the treatment of myocardial infarction and coronary heart disease in clinic." | 3.96 | Metabolomic profiling of metoprolol-induced cardioprotection in a murine model of acute myocardial ischemia. ( Kou, J; Lai, Q; Li, F; Liu, Z; Wang, H; Yu, B; Yuan, G, 2020) |
| "Metoprolol is regarded as a first-line medicine for the treatment of myocardial infarction (MI)." | 3.96 | Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats. ( Li, Z; Qin, W; Xiao, D; Xu, C; Yang, H; Zhang, H; Zhang, L; Zhang, Y, 2020) |
| "We examined whether intratracheal delivery of metoprolol can reduce ventricular rate during atrial fibrillation (AF) and accelerate conversion to sinus rhythm." | 3.96 | Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm. ( Araujo Silva, B; Belardinelli, L; Bortolotto, AL; Marum, AA; Medeiros, SA; Nearing, BD; Pedreira, GC; Tessarolo Silva, F; Verrier, RL, 2020) |
| "Background Whether chronic obstructive sleep apnea ( OSA ) could promote epicardial adipose tissue ( EAT ) secretion of profibrotic adipokines, and thereby contribute to atrial fibrosis, and the potential therapeutic effects of metoprolol remain unknown." | 3.91 | Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea. ( Dai, H; Gong, Y; Han, Y; Li, T; Li, Y; Sheng, L; Sun, L; Xu, J; Yin, S; Yuan, Y; Zhang, Y, 2019) |
| " Ginseng Fruit Saponin (GFS) and Metoprolol are two drugs which have beneficial effects on the cardiovascular system in Myocardial Infarction (MI) mice." | 3.91 | Antidepressant-like effects of ginseng fruit saponin in myocardial infarction mice. ( Ge, Y; Geng, Q; Liu, J; Liu, M; Zhang, L, 2019) |
| "Cerebral ischemia has previously been shown to cause a systemic decrease in levels of the reduced forms of low-molecular-weight aminothiols [cysteine (Cys), homocysteine (Hcy), and glutathione (GSH)] in blood plasma." | 3.88 | Metoprolol and Nebivolol Prevent the Decline of the Redox Status of Low-Molecular-Weight Aminothiols in Blood Plasma of Rats During Acute Cerebral Ischemia. ( Alexandrin, VV; Bulgakova, PO; Ivanov, AV; Kubatiev, AA; Nikiforova, KA; Paltsyn, AA; Sviridkina, NB; Virus, ED, 2018) |
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 3.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| "Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
| "Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA." | 3.81 | Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015) |
| " Nebivolol was more potent than metoprolol in improving cardiac function, pulmonary vascular remodeling, and inflammation of rats with monocrotaline-induced pulmonary hypertension." | 3.81 | Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. ( Antigny, F; Bentebbal, S; Bogaard, HJ; Dorfmüller, P; Eddahibi, S; Fadel, E; Happé, C; Humbert, M; Izikki, M; Jourdon, P; Lecerf, F; Perros, F; Ranchoux, B; Simonneau, G, 2015) |
| "The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2 -adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF)." | 3.81 | Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. ( Calzetta, L; Capuano, A; Donniacuo, M; Gritti, G; Martuscelli, E; Matera, MG; Orlandi, A; Rafaniello, C; Rinaldi, B; Rossi, F; Sodano, L, 2015) |
| "We used a New Zealand white rabbit model of cationized bovine serum albumin (cBSA)-induced glomerulonephritis and then administered them metoprolol, irbesartan or acupuncture to evaluate the effectiveness of acupuncture treatment and preliminarily explore its potential mechanism." | 3.80 | "Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity. ( An, P; Dang, HM; Shi, XM; Wu, XL; Ye, BY, 2014) |
| "The effects of metoprolol or/and BNP were studied on cardiac remodelling, excitation-contraction coupling and arrhythmias in an experimental mouse model of ischaemic heart failure following postmyocardial infarction." | 3.80 | Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? ( Aimond, F; Babuty, D; Cassan, C; Fauconnier, J; Gac, A; Karam, S; Lacampagne, A; Le Guennec, JY; Richard, S; Roberge, S; Roussel, J; Thireau, J, 2014) |
| "Mice treated with sorafenib or vehicle for 3 weeks underwent induced myocardial infarction (MI) after 1 week of treatment." | 3.80 | Sorafenib cardiotoxicity increases mortality after myocardial infarction. ( Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D, 2014) |
| "To investigate whether heart rate reduction via I(f)-channel blockade and β-receptor blockade prevents left ventricular (LV) dysfunction, we studied ivabradine and metoprolol in angiotensin II-induced heart failure." | 3.78 | Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. ( Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C, 2012) |
| " We determined to examine the effect of ILE on haemodynamic recovery following induction of hypotension with the relatively hydrophilic β-blocker, metoprolol." | 3.76 | Intravenous lipid emulsion does not augment blood pressure recovery in a rabbit model of metoprolol toxicity. ( Browne, A; Cave, G; Harvey, M, 2010) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 3.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 3.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| " Here, we show that blockade of beta-adrenoceptors directly in the brain (chronic intracerebroventricular administration of metoprolol) attenuates the progression of left ventricular remodeling in a rat model of myocardial infarction-induced heart failure." | 3.74 | Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. ( Bondar, SI; Gourine, A; Gourine, AV; Spyer, KM, 2008) |
| "Rabbit heart failure model was established by aortic insufficiency induced volume overload followed 14 days later by pressure overload induced by abdominal aorta constricting (HF, n = 11), another 8 rabbits with heart failure were treated with metoprolol (ME) for 6 weeks, sham-operated rabbits (n = 11) served as control." | 3.74 | [Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure]. ( Han, LH; Jiang, B; Jiang, TB; Jiang, WP; Li, BY; Li, HX; Liu, ZH; Song, JP; Yang, XJ; Zou, C, 2007) |
| "Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis." | 3.74 | Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. ( Ji-Fei, T; Jia-Feng, L; Jiang-Hua, R; Li-Sha, G; Peng, C; Peng-Lin, Y; Yue-Chun, L; Zhan-Qiu, Y, 2008) |
| "Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)." | 3.74 | Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008) |
| " We aimed to verify whether the beta-blocker, metoprolol, and the pure heart-rate-reducing agent, ivabradine, have the same effects on haemodynamic function, ventricular remodeling, and Ca2+ handling in post-myocardial infarction (MI) heart failure in rat." | 3.74 | Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. ( Mackiewicz, U; Maczewski, M, 2008) |
| "We compared protective effects of a ss-adrenoceptor blocker (metoprolol; Met) and a If current (Ivabradine; Iva) in a rabbit model of myocardial infarction." | 3.73 | Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction. ( Brockert, M; Gams, E; Langenbach, MR; Pomblum, VJ; Schepan, M; Schipke, JD; Schmitz-Spanke, S; Zirngibl, H, 2006) |
| "The beta1-selective blocker metoprolol was effective to prevent coronary vasospasm." | 3.73 | Differing effects of metoprolol and propranolol on large vessel and microvessel responsiveness in a porcine model of coronary spasm. ( Aikawa, K; Ishibashi, T; Maruyama, Y; Matsumoto, K; Muto, M; Onogi, F; Osugi, T; Saitoh, S, 2006) |
| "The present study addressed possible alterations in the pharmacodynamic and pharmacokinetic properties of the beta1-adrenoceptor antagonist metoprolol in experimental hypertension induced by abdominal aortic coarctation (ACo)." | 3.72 | Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ( Di Verniero, C; Höcht, C; Opezzo, JA; Taira, CA, 2004) |
| "Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)." | 3.71 | Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002) |
| "We examined dogs with coronary microembolism-induced heart failure treated for 12 weeks with metoprolol (25 mg twice daily)." | 3.70 | Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. ( Kerner, J; Panchal, AR; Sabbah, HN; Stanley, WC, 1998) |
| "We have investigated the effect of experimental malaria infection on rat cytochrome P450-mediated drug metabolism using ethoxyresorufin and metoprolol as probe compounds." | 3.69 | Possible isozyme-specific effects of experimental malaria infection with Plasmodium berghei on cytochrome P450 activity in rat liver microsomes. ( Edwards, G; Glazier, AP; Kokwaro, GO, 1994) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 3.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "In anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in the course of infarction, the smaller the infarct and the higher the LVEF." | 2.82 | Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. ( Aguero, J; Cabrera, JA; Fernández-Friera, L; Fernández-Jiménez, R; Fernández-Ortiz, A; Fuster, V; Galán-Arriola, C; García-Alvarez, A; García-Prieto, J; García-Ruiz, JM; Ibáñez, B; López-Martín, GJ; López-Melgar, B; Macías, A; Martínez-Tenorio, P; Mateos, A; Nuno-Ayala, M; Pérez-Asenjo, B; Pizarro, G; Sánchez-González, J, 2016) |
| "Mice treated with metoprolol experienced a reduced heart rate with no difference in blood pressure." | 1.91 | Beta1-receptor blockade attenuates atherosclerosis progression following traumatic brain injury in apolipoprotein E deficient mice. ( Eitzman, DT; Guo, C; Lawrence, DA; Silaghi, P; Su, EJ; Venugopal, J; Wang, J, 2023) |
| "Pretreatment with metoprolol + bromocriptine + tamsulosin rescued the retina in all genetic backgrounds, starting at doses of 0." | 1.51 | A Mixture of U.S. Food and Drug Administration-Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness. ( Choi, EH; Gardella, A; Kefalov, VJ; Leinonen, H; Palczewski, K, 2019) |
| "Metoprolol treatment did not delay the onset of heart failure symptoms, improve mitochondrial function, or regress RV hypertrophy." | 1.51 | Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment. ( Hickey, AJ; Jones, TLM; Norman, R; Power, AS; Ward, ML, 2019) |
| "Ventricular arrhythmias (VAs) are the leading cause of sudden cardiac death in patients with myocardial infarction (MI)." | 1.48 | Comparison between renal denervation and metoprolol on the susceptibility of ventricular arrhythmias in rats with myocardial infarction. ( Chen, C; Geng, J; Huo, J; Jiang, W; Jiang, Z; Lu, D; Shan, Q; Xu, H, 2018) |
| "Most patients with Duchenne muscular dystrophy (DMD) will develop cardiomyopathy; however, the evidence for prophylactic treatment of children with cardiac medications is limited." | 1.42 | Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice. ( Blain, A; Blamire, AM; Greally, E; Laval, SH; MacGowan, GA; Straub, VW, 2015) |
| "Pretreatment with propranolol and metoprolol improved survival to 90% and 100% respectively, compared with 60% in the ISO group, but did not reduce the incidence and extent of akinesis or the structural damage." | 1.40 | Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy. ( Dai, W; Kloner, RA; Sachdeva, J, 2014) |
| "Metoprolol pretreatment reduced post-CME myocardial apoptosis possibly through downregulating death receptor-mediated apoptotic pathway." | 1.39 | [Effects of pretreatment with metoprolol on cardiomyocyte apoptosis and caspase-8 activation after coronary microembolization in rats]. ( Li, L; Lu, YG; Su, Q; Wang, JY; Wen, WM; Zhou, Y, 2013) |
| "Patients in cardiac arrest are often taking medications affecting adrenergic activity such as the beta blocker metoprolol and the combined alpha and beta blocker, labetalol." | 1.38 | Beta-blockade causes a reduction in the frequency spectrum of VF but improves resuscitation outcome: A potential limitation of quantitative waveform measures. ( Niemann, J; Rosborough, JP; Shah, AP; Sherman, L; Youngquist, ST, 2012) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model." | 1.37 | Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011) |
| "Treatment with metoprolol decreased systolic blood pressure at 21 months only but improved survival, decreased ventricular weight, prevented chamber dilation, reduced inflammation, decreased fibrosis, attenuated action potential prolongation, improved systolic and diastolic function, decreased stiffness and improved endothelium-independent vascular responses." | 1.37 | Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. ( Brown, L; Chan, V; Fenning, A; Hoey, A, 2011) |
| "Metoprolol was given orally (2." | 1.36 | Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Laval, S; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| "Hypertension is associated with left ventricular hypertrophy (LVH) and diastolic dysfunction." | 1.35 | Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits. ( Bousquet, PP; Monassier, LJ; Signolet, IL, 2008) |
| "This study of metoprolol pharmacokinetic and pharmacodynamic properties investigates cardiac beta1-adrenoceptors activity and its involvement in the hypertensive stage in 6-week-old fructose-fed male Sprague-Dawley rats." | 1.35 | In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. ( Di Verniero, CA; Höcht, C; Mayer, MA; Opezzo, JA; Silberman, EA; Taira, CA, 2008) |
| "Treatment with metoprolol had no effect on PCr/ATP and LV function." | 1.32 | Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. ( Bollano, E; Omerovic, E; Soussi, B; Waagstein, F, 2003) |
| "To investigate the mechanism responsible for the increased bioavailability of propranolol in bilateral ureter-ligated (BUL) rats, the intestinal absorption and hepatic extraction of propranolol and metoprolol were evaluated." | 1.32 | Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation. ( Hashimoto, Y; Higashi, T; Ohta, T; Okabe, H, 2004) |
| "Hemorrhagic shock is associated with increasing catecholamine plasma concentrations." | 1.31 | Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression. ( Nickel, E; Oberbeck, R; Pape, HC; Tschernig, T; van Griensven, M; Wittwer, T, 2002) |
| "Metoprolol (6 mg." | 1.28 | Metoprolol and ventricular repolarisation and refractoriness: lack of chronic adaptational class III effects in rabbit. ( Barr, SM; Cobbe, SM; Manley, BS, 1991) |
| "The metoprolol-treated animals in groups 1 and 2 had a reduction of atherosclerosis compared with their respective controls." | 1.27 | Atherosclerosis in rabbits identified as high and low responders to an atherogenic diet and the effect of treatment with a beta 1-blocker. ( Bondjers, G; Bräutigam, J; Lindqvist, P; Nordborg, C; Olsson, G; Ostlund-Lindqvist, AM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.36) | 18.7374 |
| 1990's | 10 (8.40) | 18.2507 |
| 2000's | 40 (33.61) | 29.6817 |
| 2010's | 52 (43.70) | 24.3611 |
| 2020's | 13 (10.92) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Li, P | 2 |
| Robertson, TA | 2 |
| Thorling, CA | 1 |
| Zhang, Q | 2 |
| Fletcher, LM | 2 |
| Crawford, DH | 2 |
| Roberts, MS | 2 |
| Xue, ST | 1 |
| Zhang, L | 3 |
| Xie, ZS | 1 |
| Jin, J | 1 |
| Guo, HF | 1 |
| Yi, H | 1 |
| Liu, ZY | 1 |
| Li, ZR | 1 |
| Chen, C | 2 |
| Tian, J | 1 |
| He, Z | 2 |
| Xiong, W | 1 |
| He, Y | 1 |
| Liu, S | 1 |
| Wang, J | 3 |
| Venugopal, J | 1 |
| Silaghi, P | 1 |
| Su, EJ | 1 |
| Guo, C | 1 |
| Lawrence, DA | 1 |
| Eitzman, DT | 1 |
| Qin, W | 1 |
| Li, Z | 1 |
| Xiao, D | 1 |
| Zhang, Y | 4 |
| Yang, H | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Marum, AA | 1 |
| Araujo Silva, B | 1 |
| Bortolotto, AL | 1 |
| Pedreira, GC | 1 |
| Tessarolo Silva, F | 1 |
| Medeiros, SA | 1 |
| Nearing, BD | 2 |
| Belardinelli, L | 3 |
| Verrier, RL | 3 |
| Yang, L | 1 |
| Zhao, J | 3 |
| Qu, Y | 1 |
| Sun, Q | 1 |
| Li, TT | 1 |
| Yan, ML | 1 |
| Duan, MJ | 1 |
| Li, KX | 1 |
| Wang, YR | 1 |
| Huang, SY | 1 |
| Zhang, S | 2 |
| Li, Y | 6 |
| Ai, J | 1 |
| Lai, Q | 1 |
| Yuan, G | 1 |
| Wang, H | 1 |
| Liu, Z | 2 |
| Kou, J | 1 |
| Yu, B | 1 |
| Li, F | 1 |
| Bussey, CT | 1 |
| Babakr, AA | 1 |
| Iremonger, RR | 1 |
| van Hout, I | 1 |
| Wilkins, GT | 1 |
| Lamberts, RR | 1 |
| Erickson, JR | 1 |
| Razzoli, M | 1 |
| Lindsay, A | 1 |
| Law, ML | 1 |
| Chamberlain, CM | 1 |
| Southern, WM | 1 |
| Berg, M | 1 |
| Osborn, J | 1 |
| Engeland, WC | 1 |
| Metzger, JM | 1 |
| Ervasti, JM | 1 |
| Bartolomucci, A | 1 |
| Tan, S | 1 |
| Zhou, F | 1 |
| Zhang, Z | 1 |
| Xu, J | 2 |
| Zhuang, Q | 1 |
| Meng, Q | 1 |
| Xi, Q | 1 |
| Jiang, Y | 1 |
| Wu, G | 1 |
| Pearson, JT | 1 |
| Thambyah, HP | 1 |
| Waddingham, MT | 1 |
| Inagaki, T | 1 |
| Sukumaran, V | 1 |
| Ngo, JP | 1 |
| Ow, CPC | 1 |
| Sonobe, T | 1 |
| Chen, YC | 1 |
| Edgley, AJ | 1 |
| Fujii, Y | 1 |
| Du, CK | 2 |
| Zhan, DY | 2 |
| Umetani, K | 1 |
| Kelly, DJ | 1 |
| Tsuchimochi, H | 1 |
| Shirai, M | 1 |
| Bin Jardan, YA | 1 |
| Ahad, A | 1 |
| Raish, M | 1 |
| Alam, MA | 1 |
| Al-Mohizea, AM | 1 |
| Al-Jenoobi, FI | 1 |
| Sun, L | 3 |
| Yan, S | 2 |
| Wang, X | 3 |
| Zhao, S | 1 |
| Li, H | 2 |
| Wang, Y | 1 |
| Lu, S | 1 |
| Dong, X | 2 |
| Yu, S | 1 |
| Li, M | 1 |
| Zhang, K | 1 |
| Tang, YD | 1 |
| Ojamaa, K | 1 |
| Saini, AS | 1 |
| Carrillo-Sepulveda, MA | 1 |
| Rajagopalan, V | 1 |
| Gerdes, AM | 1 |
| Eibel, B | 1 |
| Kristochek, M | 1 |
| Peres, TR | 1 |
| Dias, LD | 1 |
| Dartora, DR | 1 |
| Casali, KR | 1 |
| Kalil, RAK | 1 |
| Lehnen, AM | 1 |
| Irigoyen, MC | 2 |
| Markoski, MM | 1 |
| Jiang, W | 1 |
| Huo, J | 1 |
| Lu, D | 1 |
| Jiang, Z | 1 |
| Geng, J | 1 |
| Xu, H | 1 |
| Shan, Q | 1 |
| Khwaja, S | 1 |
| Mahmood, T | 1 |
| Siddiqui, HH | 1 |
| Ivanov, AV | 1 |
| Alexandrin, VV | 1 |
| Paltsyn, AA | 1 |
| Virus, ED | 1 |
| Nikiforova, KA | 1 |
| Bulgakova, PO | 1 |
| Sviridkina, NB | 1 |
| Kubatiev, AA | 1 |
| Dai, H | 1 |
| Yuan, Y | 1 |
| Yin, S | 1 |
| Han, Y | 1 |
| Li, T | 1 |
| Sheng, L | 1 |
| Gong, Y | 1 |
| Yamamoto, H | 1 |
| Kawada, T | 1 |
| Shimizu, S | 1 |
| Hayama, Y | 1 |
| Shishido, T | 1 |
| Iwanaga, Y | 1 |
| Fukuda, K | 1 |
| Miyazaki, S | 1 |
| Sugimachi, M | 1 |
| Leinonen, H | 1 |
| Choi, EH | 1 |
| Gardella, A | 1 |
| Kefalov, VJ | 1 |
| Palczewski, K | 1 |
| Power, AS | 1 |
| Norman, R | 1 |
| Jones, TLM | 1 |
| Hickey, AJ | 1 |
| Ward, ML | 1 |
| Liu, M | 1 |
| Liu, J | 1 |
| Geng, Q | 1 |
| Ge, Y | 1 |
| Qi, C | 1 |
| Shao, Y | 1 |
| Liu, X | 1 |
| Wang, D | 3 |
| Li, X | 2 |
| Patel, BM | 1 |
| Bhadada, SV | 1 |
| Su, Q | 1 |
| Li, L | 2 |
| Zhou, Y | 1 |
| Wang, JY | 1 |
| Wen, WM | 1 |
| Lu, YG | 1 |
| Thireau, J | 1 |
| Karam, S | 1 |
| Roberge, S | 1 |
| Roussel, J | 1 |
| Aimond, F | 1 |
| Cassan, C | 1 |
| Gac, A | 1 |
| Babuty, D | 1 |
| Le Guennec, JY | 1 |
| Lacampagne, A | 1 |
| Fauconnier, J | 1 |
| Richard, S | 1 |
| Duran, JM | 1 |
| Makarewich, CA | 1 |
| Trappanese, D | 1 |
| Gross, P | 1 |
| Husain, S | 1 |
| Dunn, J | 1 |
| Lal, H | 1 |
| Sharp, TE | 1 |
| Starosta, T | 1 |
| Vagnozzi, RJ | 1 |
| Berretta, RM | 1 |
| Barbe, M | 1 |
| Yu, D | 2 |
| Gao, E | 2 |
| Kubo, H | 1 |
| Force, T | 1 |
| Houser, SR | 2 |
| Rinaldi, B | 2 |
| Capuano, A | 2 |
| Gritti, G | 2 |
| Donniacuo, M | 3 |
| Scotto Di Vettimo, A | 1 |
| Sodano, L | 2 |
| Rafaniello, C | 2 |
| Rossi, F | 2 |
| Matera, MG | 2 |
| Zhang, F | 1 |
| Zhan, Q | 1 |
| Jiang, B | 2 |
| Gao, S | 1 |
| Tao, X | 1 |
| Chen, W | 1 |
| An, P | 1 |
| Dang, HM | 1 |
| Shi, XM | 1 |
| Ye, BY | 1 |
| Wu, XL | 1 |
| Sachdeva, J | 1 |
| Dai, W | 1 |
| Kloner, RA | 1 |
| Ahiskalioglu, A | 1 |
| Ince, I | 1 |
| Aksoy, M | 1 |
| Ahiskalioglu, EO | 1 |
| Comez, M | 1 |
| Dostbil, A | 1 |
| Celik, M | 1 |
| Alp, HH | 1 |
| Coskun, R | 1 |
| Taghizadehghalehjoughi, A | 1 |
| Suleyman, B | 1 |
| Erokhina, IL | 1 |
| Voronchikhin, PA | 1 |
| Okovityĭ, SV | 1 |
| Emel'ianova, OI | 1 |
| Perros, F | 1 |
| Ranchoux, B | 1 |
| Izikki, M | 1 |
| Bentebbal, S | 1 |
| Happé, C | 1 |
| Antigny, F | 1 |
| Jourdon, P | 1 |
| Dorfmüller, P | 1 |
| Lecerf, F | 1 |
| Fadel, E | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Bogaard, HJ | 1 |
| Eddahibi, S | 1 |
| Ye, Y | 1 |
| Gong, H | 1 |
| Wu, J | 1 |
| Wang, S | 1 |
| Yuan, J | 1 |
| Yin, P | 1 |
| Jiang, G | 1 |
| Ding, Z | 1 |
| Zhang, W | 1 |
| Zhou, J | 1 |
| Ge, J | 1 |
| Zou, Y | 1 |
| Martuscelli, E | 1 |
| Orlandi, A | 1 |
| Calzetta, L | 1 |
| Blain, A | 2 |
| Greally, E | 2 |
| Laval, SH | 1 |
| Blamire, AM | 1 |
| MacGowan, GA | 2 |
| Straub, VW | 1 |
| Li, W | 1 |
| Ding, X | 1 |
| Liu, L | 1 |
| Peng, W | 1 |
| Suita, K | 1 |
| Fujita, T | 1 |
| Hasegawa, N | 1 |
| Cai, W | 1 |
| Jin, H | 1 |
| Hidaka, Y | 1 |
| Prajapati, R | 1 |
| Umemura, M | 1 |
| Yokoyama, U | 1 |
| Sato, M | 1 |
| Okumura, S | 1 |
| Ishikawa, Y | 1 |
| Yue, Y | 1 |
| Dou, L | 1 |
| Xue, H | 1 |
| Song, Y | 1 |
| García-Ruiz, JM | 1 |
| Fernández-Jiménez, R | 1 |
| García-Alvarez, A | 1 |
| Pizarro, G | 1 |
| Galán-Arriola, C | 1 |
| Fernández-Friera, L | 1 |
| Mateos, A | 1 |
| Nuno-Ayala, M | 1 |
| Aguero, J | 1 |
| Sánchez-González, J | 1 |
| García-Prieto, J | 1 |
| López-Melgar, B | 1 |
| Martínez-Tenorio, P | 1 |
| López-Martín, GJ | 1 |
| Macías, A | 1 |
| Pérez-Asenjo, B | 1 |
| Cabrera, JA | 1 |
| Fernández-Ortiz, A | 1 |
| Fuster, V | 1 |
| Ibáñez, B | 2 |
| Zang, Y | 1 |
| Tan, Q | 1 |
| Ma, X | 1 |
| Zhao, X | 2 |
| Lei, W | 1 |
| Grisanti, LA | 1 |
| Gumpert, AM | 1 |
| Traynham, CJ | 1 |
| Gorsky, JE | 1 |
| Repas, AA | 1 |
| Carter, RL | 1 |
| Calvert, JW | 1 |
| García, AP | 1 |
| Rabinowitz, JE | 2 |
| Koch, WJ | 2 |
| Tilley, DG | 1 |
| Vaillant, F | 1 |
| Lauzier, B | 1 |
| Ruiz, M | 1 |
| Shi, Y | 1 |
| Lachance, D | 3 |
| Rivard, ME | 1 |
| Bolduc, V | 2 |
| Thorin, E | 2 |
| Tardif, JC | 2 |
| Des Rosiers, C | 2 |
| Nazeri, A | 1 |
| Elayda, MA | 1 |
| Segura, AM | 1 |
| Stainback, RF | 1 |
| Nathan, J | 1 |
| Lee, VV | 1 |
| Bove, C | 1 |
| Sampaio, L | 1 |
| Grace, B | 1 |
| Massumi, A | 1 |
| Razavi, M | 1 |
| Oosterhuis, NR | 1 |
| Bongartz, LG | 1 |
| Verhaar, MC | 1 |
| Cheng, C | 1 |
| Xu, YJ | 1 |
| van Koppen, A | 1 |
| Cramer, MJ | 1 |
| Goldschmeding, R | 1 |
| Gaillard, CA | 1 |
| Doevendans, PA | 1 |
| Braam, B | 1 |
| Joles, JA | 1 |
| Hanada, K | 1 |
| Asari, K | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Mita, M | 1 |
| Ogata, H | 1 |
| Bartholomeu, JB | 1 |
| Vanzelli, AS | 2 |
| Rolim, NP | 1 |
| Ferreira, JC | 1 |
| Bechara, LR | 1 |
| Tanaka, LY | 1 |
| Rosa, KT | 1 |
| Alves, MM | 1 |
| Medeiros, A | 2 |
| Mattos, KC | 1 |
| Coelho, MA | 1 |
| Krieger, EM | 1 |
| Krieger, JE | 1 |
| Negrão, CE | 1 |
| Ramires, PR | 1 |
| Guatimosim, S | 1 |
| Brum, PC | 2 |
| Rastogi, S | 3 |
| Sharov, VG | 3 |
| Mishra, S | 3 |
| Gupta, RC | 3 |
| Blackburn, B | 1 |
| Stanley, WC | 3 |
| Sabbah, HN | 6 |
| Zacà, V | 1 |
| Wang, M | 1 |
| Goldstein, S | 2 |
| Pat, B | 1 |
| Killingsworth, C | 1 |
| Denney, T | 1 |
| Zheng, J | 1 |
| Powell, P | 1 |
| Tillson, M | 1 |
| Dillon, AR | 2 |
| Dell'Italia, LJ | 3 |
| Kato, H | 1 |
| Kawaguchi, M | 1 |
| Inoue, S | 1 |
| Hirai, K | 1 |
| Furuya, H | 1 |
| Sun, T | 1 |
| Shen, LH | 1 |
| Chen, H | 1 |
| Li, HW | 1 |
| Guo, CY | 1 |
| Li, ZZ | 1 |
| Tang, CS | 1 |
| Rengo, G | 1 |
| Lymperopoulos, A | 1 |
| Zincarelli, C | 1 |
| Soltys, S | 1 |
| Champetier, S | 2 |
| Bojmehrani, A | 1 |
| Beaudoin, J | 1 |
| Plante, E | 2 |
| Roussel, E | 2 |
| Couet, J | 2 |
| Arsenault, M | 2 |
| Izumi, Y | 1 |
| Okatani, H | 1 |
| Shiota, M | 1 |
| Nakao, T | 1 |
| Ise, R | 1 |
| Kito, G | 1 |
| Miura, K | 1 |
| Iwao, H | 1 |
| Morimoto, S | 1 |
| Wang, YY | 1 |
| Lu, QW | 1 |
| Tanaka, A | 1 |
| Ide, T | 1 |
| Miwa, Y | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| Liu, Q | 1 |
| Chen, X | 1 |
| Macdonnell, SM | 1 |
| Kranias, EG | 1 |
| Lorenz, JN | 1 |
| Leitges, M | 1 |
| Molkentin, JD | 1 |
| Aguilar-Torres, R | 1 |
| Browne, A | 1 |
| Harvey, M | 1 |
| Cave, G | 1 |
| Bauer, R | 1 |
| Bushby, K | 1 |
| Lochmüller, H | 1 |
| Laval, S | 1 |
| Straub, V | 1 |
| Sirvente, Rde A | 1 |
| Salemi, VM | 1 |
| Mady, C | 1 |
| Lu, Y | 1 |
| Huang, W | 1 |
| Wen, W | 1 |
| George, I | 1 |
| Xu, K | 1 |
| Wang, N | 1 |
| Fang, Y | 1 |
| Nicol, L | 1 |
| Harouki, N | 1 |
| Monteil, C | 1 |
| Wecker, D | 1 |
| Debunne, M | 1 |
| Bauer, F | 1 |
| Lallemand, F | 1 |
| Richard, V | 1 |
| Thuillez, C | 1 |
| Mulder, P | 1 |
| Chan, V | 1 |
| Fenning, A | 1 |
| Hoey, A | 1 |
| Brown, L | 1 |
| Kar, S | 1 |
| Gao, L | 1 |
| Belatti, DA | 1 |
| Curry, PL | 1 |
| Zucker, IH | 1 |
| Richardson, ES | 1 |
| Rolfes, C | 1 |
| Woo, OS | 1 |
| Elmquist, WF | 1 |
| Benditt, DG | 1 |
| Iaizzo, PA | 1 |
| Drouin, A | 1 |
| Gillis, MA | 1 |
| Duquette, N | 1 |
| Thorin-Trescases, N | 1 |
| Frayne-Robillard, I | 1 |
| Sherman, L | 1 |
| Niemann, J | 1 |
| Youngquist, ST | 1 |
| Shah, AP | 1 |
| Rosborough, JP | 1 |
| Weiss, M | 1 |
| Hamada, N | 1 |
| Nishi, Y | 1 |
| Tajiri, Y | 1 |
| Setoyama, K | 1 |
| Kamimura, R | 1 |
| Miyahara, K | 1 |
| Nuruki, N | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Kojima, M | 1 |
| Mifune, H | 1 |
| Becher, PM | 1 |
| Lindner, D | 1 |
| Miteva, K | 1 |
| Savvatis, K | 1 |
| Zietsch, C | 1 |
| Schmack, B | 1 |
| Van Linthout, S | 1 |
| Westermann, D | 2 |
| Schultheiss, HP | 2 |
| Tschöpe, C | 2 |
| Ishikura, F | 1 |
| Takano, Y | 1 |
| Ueyama, T | 1 |
| Oberbeck, R | 1 |
| van Griensven, M | 1 |
| Nickel, E | 1 |
| Tschernig, T | 1 |
| Wittwer, T | 1 |
| Pape, HC | 1 |
| Höcht, C | 4 |
| Di Verniero, C | 2 |
| Opezzo, JA | 4 |
| Taira, CA | 4 |
| Tallaj, J | 1 |
| Wei, CC | 1 |
| Hankes, GH | 1 |
| Holland, M | 1 |
| Rynders, P | 1 |
| Ardell, JL | 1 |
| Armour, JA | 1 |
| Lucchesi, PA | 1 |
| Omerovic, E | 1 |
| Bollano, E | 1 |
| Soussi, B | 1 |
| Waagstein, F | 1 |
| Inoue, A | 1 |
| Yamashina, S | 1 |
| Yamazaki, J | 1 |
| Okabe, H | 1 |
| Higashi, T | 1 |
| Ohta, T | 1 |
| Hashimoto, Y | 1 |
| Kobayashi, M | 1 |
| Machida, N | 1 |
| Mitsuishi, M | 1 |
| Yamane, Y | 1 |
| Dorenkamp, M | 1 |
| Riad, A | 1 |
| Stiehl, S | 1 |
| Spillmann, F | 1 |
| Du, J | 1 |
| Pauschinger, M | 1 |
| Noutsias, M | 1 |
| Adams, V | 1 |
| Ahmet, I | 1 |
| Lakatta, EG | 1 |
| Talan, MI | 1 |
| Langenbach, MR | 1 |
| Schmitz-Spanke, S | 1 |
| Brockert, M | 1 |
| Schepan, M | 1 |
| Pomblum, VJ | 1 |
| Gams, E | 1 |
| Zirngibl, H | 1 |
| Schipke, JD | 1 |
| Muto, M | 1 |
| Saitoh, S | 1 |
| Osugi, T | 1 |
| Matsumoto, K | 1 |
| Aikawa, K | 1 |
| Onogi, F | 1 |
| Ishibashi, T | 1 |
| Maruyama, Y | 2 |
| Imai, M | 1 |
| Mika, Y | 1 |
| Rousso, B | 1 |
| Burkhoff, D | 1 |
| Ben-Haim, S | 1 |
| Ablad, B | 1 |
| Bjurö, T | 1 |
| Björkman, JA | 1 |
| Edström, T | 1 |
| Zou, C | 1 |
| Liu, ZH | 1 |
| Song, JP | 1 |
| Jiang, TB | 1 |
| Yang, XJ | 1 |
| Li, HX | 1 |
| Han, LH | 1 |
| Li, BY | 1 |
| Jiang, WP | 1 |
| Signolet, IL | 1 |
| Bousquet, PP | 1 |
| Monassier, LJ | 1 |
| Li, JJ | 1 |
| Qu, XF | 1 |
| Li, KS | 1 |
| Yu, Y | 1 |
| Xi, Y | 1 |
| Yue, L | 1 |
| Wang, GZ | 1 |
| Huang, YL | 1 |
| Yue-Chun, L | 1 |
| Li-Sha, G | 1 |
| Jiang-Hua, R | 1 |
| Peng-Lin, Y | 1 |
| Jia-Feng, L | 1 |
| Ji-Fei, T | 1 |
| Peng, C | 1 |
| Zhan-Qiu, Y | 1 |
| Lujan, HL | 1 |
| Dicarlo, SE | 1 |
| Drolet, MC | 1 |
| Maczewski, M | 1 |
| Mackiewicz, U | 1 |
| Gourine, A | 1 |
| Bondar, SI | 1 |
| Spyer, KM | 1 |
| Gourine, AV | 1 |
| Sabri, A | 1 |
| Rafiq, K | 1 |
| Seqqat, R | 1 |
| Kolpakov, MA | 1 |
| Dillon, R | 1 |
| Di Verniero, CA | 1 |
| Silberman, EA | 1 |
| Mayer, MA | 1 |
| Lu, HR | 1 |
| Remeysen, P | 1 |
| De Clerck, F | 1 |
| Zmudka, K | 2 |
| Dubiel, J | 2 |
| Vanhaecke, J | 2 |
| Flameng, W | 2 |
| De Geest, H | 2 |
| Glazier, AP | 1 |
| Kokwaro, GO | 1 |
| Edwards, G | 1 |
| Cherng, WJ | 1 |
| Liang, CS | 1 |
| Hood, WB | 1 |
| Aubert, A | 1 |
| Kaczmarek, J | 1 |
| Shimoyama, H | 1 |
| Rosman, H | 1 |
| Alam, M | 1 |
| Panchal, AR | 1 |
| Kerner, J | 1 |
| Kovach, JA | 1 |
| Yaoita, H | 1 |
| Sakabe, A | 1 |
| Maehara, K | 1 |
| Samizadeh, A | 1 |
| Losse, H | 1 |
| Wessels, F | 1 |
| Barr, SM | 1 |
| Manley, BS | 1 |
| Cobbe, SM | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| O'Brien, RC | 1 |
| Papazoglou, D | 1 |
| Clarke, BE | 1 |
| Jerums, G | 1 |
| Doyle, AE | 1 |
| Kirby, DA | 1 |
| Hottinger, S | 1 |
| Ravid, S | 1 |
| Lown, B | 1 |
| Ruffolo, RR | 1 |
| Kopia, GA | 1 |
| Zimmer, HG | 1 |
| Zierhut, W | 1 |
| Marschner, G | 1 |
| Lindqvist, P | 1 |
| Olsson, G | 1 |
| Nordborg, C | 1 |
| Bondjers, G | 1 |
| Bräutigam, J | 1 |
| Ostlund-Lindqvist, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.[NCT01052532] | 65 participants (Actual) | Observational | 2005-06-30 | Completed | |||
| Italian Registry on Cardiac Contractility Modulation Therapy[NCT04327323] | 200 participants (Anticipated) | Observational [Patient Registry] | 2019-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
2 reviews available for metoprolol and Disease Models, Animal
| Article | Year |
|---|---|
Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.
Topics: Administration, Inhalation; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, An | 2020 |
Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Dogs; | 1986 |
2 trials available for metoprolol and Disease Models, Animal
| Article | Year |
|---|---|
Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models, Animal; Drug Administration Schedul | 2016 |
Prevention of ventricular fibrillation requires central beta-adrenoceptor blockade in rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Baroreflex; Blood Pressure; Central Nervous System; | 2007 |
115 other studies available for metoprolol and Disease Models, Animal
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cations; Cytochrome P-450 | 2011 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Respo | 2020 |
Identified Three Interferon Induced Proteins as Novel Biomarkers of Human Ischemic Cardiomyopathy.
Topics: Animals; Apoptosis Regulatory Proteins; Biomarkers; Cardiomyopathies; Disease Models, Animal; Gene R | 2021 |
Beta1-receptor blockade attenuates atherosclerosis progression following traumatic brain injury in apolipoprotein E deficient mice.
Topics: Adrenergic beta-Antagonists; Animals; Atherosclerosis; Blood Pressure; Brain Injuries, Traumatic; Di | 2023 |
Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Cell Communication; Cells, Cultured; Connexin 43; D | 2020 |
Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm.
Topics: Administration, Inhalation; Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Arrhythmia Agents; | 2020 |
Metoprolol prevents neuronal dendrite remodeling in a canine model of chronic obstructive sleep apnea.
Topics: Animals; Chronic Disease; Dendrites; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; | 2020 |
Metabolomic profiling of metoprolol-induced cardioprotection in a murine model of acute myocardial ischemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Male; Metabolomics; Metoprolol; Mice; Mice, Inb | 2020 |
Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Animals; Carvedilol; Coronary Artery Bypass; Diabetes | 2020 |
Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Disease Models, Animal; Dystrophin; Gait Di | 2020 |
Beta-1 blocker reduces inflammation and preserves intestinal barrier function after open abdominal surgery.
Topics: Abdomen; Adrenergic beta-1 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Cytokines; Diges | 2021 |
β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Carvedilol; Coronary A | 2021 |
Effects of garden cress, fenugreek and black seed on the pharmacodynamics of metoprolol: an herb-drug interaction study in rats with hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP2D6; Disease Models, Animal; H | 2021 |
Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria.
Topics: Adrenergic beta-1 Receptor Antagonists; AMP-Activated Protein Kinase Kinases; Animals; Atrial Fibril | 2017 |
Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Echocardiography; Ele | 2018 |
β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agent | 2018 |
Comparison between renal denervation and metoprolol on the susceptibility of ventricular arrhythmias in rats with myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Connexin 43; Denervation; Disease Models, Animal; Drug Administration | 2018 |
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarker | 2016 |
Metoprolol and Nebivolol Prevent the Decline of the Redox Status of Low-Molecular-Weight Aminothiols in Blood Plasma of Rats During Acute Cerebral Ischemia.
Topics: Acute Disease; Adrenergic beta-1 Receptor Antagonists; Animals; Brain Ischemia; Cerebrovascular Circ | 2018 |
Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea.
Topics: Adipokines; Adipose Tissue; Animals; Cardiomyopathies; Chronic Disease; Disease Models, Animal; Dogs | 2019 |
Acute effects of intravenous carvedilol versus metoprolol on baroreflex-mediated sympathetic circulatory regulation in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Baroreflex | 2019 |
A Mixture of U.S. Food and Drug Administration-Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Arrestins; | 2019 |
Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment.
Topics: Adenosine Triphosphatases; Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Animals; Di | 2019 |
Antidepressant-like effects of ginseng fruit saponin in myocardial infarction mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depression; Disease Models, Anima | 2019 |
The cardioprotective effects of icariin on the isoprenaline-induced takotsubo-like rat model: Involvement of reactive oxygen species and the TLR4/NF-κB signaling pathway.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Fibrosis; Flavonoids; Humans; | 2019 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
[Effects of pretreatment with metoprolol on cardiomyocyte apoptosis and caspase-8 activation after coronary microembolization in rats].
Topics: Animals; Apoptosis; Caspase 8; Coronary Occlusion; Disease Models, Animal; Embolism; Ischemic Precon | 2013 |
Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Re | 2014 |
Sorafenib cardiotoxicity increases mortality after myocardial infarction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cats; Cell Proliferation; Cells, Cultured; Disease Models | 2014 |
Effects of chronic administration of β-blockers on airway responsiveness in a murine model of heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Bro | 2014 |
Shengxian decoction in chronic heart failure treatment and synergistic property of Platycodonis Radix: a metabolomic approach and its application.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drugs, Chinese Herbal; Gene Expression Regulation; | 2014 |
"Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity.
Topics: Acupuncture Therapy; Animals; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Glome | 2014 |
Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Echo | 2014 |
Comparative Investigation of Protective Effects of Metyrosine and Metoprolol Against Ketamine Cardiotoxicity in Rats.
Topics: alpha-Methyltyrosine; Animals; Antioxidants; Biomarkers; Cytoprotection; Disease Models, Animal; DNA | 2015 |
[Reaction of population of pulmonary mast cells in rat bronchial asthma under the effect of β-adrenoreceptor antagonists].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alcian Blue; Animals; Anti-Asthmat | 2013 |
Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzopyrans; Cell Communication; Cell Culture Techn | 2015 |
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2015 |
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Blood Pressure | 2015 |
Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium; Captopril; | 2015 |
Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea.
Topics: Actins; Animals; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-Associated De | 2015 |
Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through β1- and α1-Adrenergic Receptor-Mediated Signaling in Mice.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atrial Fibrillation; Calcium Sig | 2015 |
Screening β1AR inhibitors by cell membrane chromatography and offline UPLC/MS method for protecting myocardial ischemia.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Apoptosis; Berberine; Binding, Competitive; Cell Me | 2015 |
Osteogenic actions of metoprolol in an ovariectomized rat model of menopause.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bone Density; Disease Models, Animal; Female; Human | 2016 |
Leukocyte-Expressed β2-Adrenergic Receptors Are Essential for Survival After Acute Myocardial Injury.
Topics: Aged; Aged, 80 and over; Animals; Disease Models, Animal; Female; Genetic Vectors; Heart Rupture; Hu | 2016 |
Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzazepines; Bradycardia; Cardiovascular Agents; D | 2016 |
Comparative Efficacy of Nebivolol and Metoprolol to Prevent Tachycardia-Induced Cardiomyopathy in a Porcine Model.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Cardiac Pacing, Artificial; Cardiomyopathies; Disea | 2016 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardio | 2008 |
Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Disease Models, Animal; Dogs; Drug Therapy, Combinat | 2009 |
Dissociation between cardiomyocyte function and remodeling with beta-adrenergic receptor blockade in isolated canine mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anima | 2008 |
The effects of beta-adrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Butoxamine; Disease Mo | 2009 |
[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Fibr | 2008 |
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di | 2009 |
Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the beta-adrenergic and renin-angiotensin systems.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorti | 2009 |
Effects of metoprolol on epinephrine-induced takotsubo-like left ventricular dysfunction in non-human primates.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Epinephrine; Gene Expression; Heart Ve | 2009 |
Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dis | 2009 |
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Signaling; Cardiomegaly; Disease Models, Animal; Fibro | 2009 |
Found in translation: metoprolol improves survival more than carvedilol in a mouse model of inherited dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Model | 2009 |
Intravenous lipid emulsion does not augment blood pressure recovery in a rabbit model of metoprolol toxicity.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Disease Mod | 2010 |
Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models | 2010 |
Association of physical training with beta-blockers in heart failure in mice.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin | 2010 |
Beta blocker metoprolol protects against contractile dysfunction in rats after coronary microembolization by regulating expression of myocardial inflammatory cytokines.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models, Animal; Echocardiography; Embolism; | 2011 |
β-adrenergic receptor blockade reduces endoplasmic reticulum stress and normalizes calcium handling in a coronary embolization model of heart failure in canines.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Apoptosis; Blotting, Western; Calcium; C | 2011 |
Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzopyrans; Disease Models, Animal; Endothelium, V | 2011 |
Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat.
Topics: Adrenergic beta-1 Receptor Antagonists; Aging; Animals; Blood Pressure; Disease Models, Animal; Dose | 2011 |
Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Chronic Disease; Consci | 2011 |
Cardiac responses to the intrapericardial delivery of metoprolol: targeted delivery compared to intravenous administration.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Function, Right; Blood Pressure; Disease Models, Animal; Ele | 2012 |
Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.
Topics: Animals; Anti-Arrhythmia Agents; Apolipoproteins B; Atherosclerosis; Benzazepines; Carotid Arteries; | 2011 |
Beta-blockade causes a reduction in the frequency spectrum of VF but improves resuscitation outcome: A potential limitation of quantitative waveform measures.
Topics: Adrenergic beta-Antagonists; Animals; Cardiopulmonary Resuscitation; Confidence Intervals; Disease M | 2012 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nuc | 2012 |
Acute effects of beta-blocker with intrinsic sympathomimetic activity on stress-induced cardiac dysfunction in rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Celiprolol; Disease Mo | 2012 |
Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2002 |
In vivo and in vitro pharmacodynamic properties of metoprolol in aortic coarctated rats.
Topics: Animals; Aortic Coarctation; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Dru | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Anterior hypothalamic beta-adrenergic activity in the maintenance of hypertension in aortic coarctated rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anterior Hypothalamic Nucleus; Aorti | 2004 |
Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Echocardiography | 2003 |
The effect of beta-blocker on hamster model BIO 53.58 with dilated cardiomyopathy determined using 123I-MIBG myocardial scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiomyopathy, Dilated; Ca | 2003 |
Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats.
Topics: Animals; Aortic Coarctation; Blood Pressure; Bradycardia; Chronic Disease; Disease Models, Animal; D | 2004 |
Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation.
Topics: Adrenergic beta-Antagonists; Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; Glucok | 2004 |
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp | 2004 |
Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2005 |
Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2005 |
Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Benzazepines; Blood Flow Velocity; Cardiotonic Agents; | 2006 |
Differing effects of metoprolol and propranolol on large vessel and microvessel responsiveness in a porcine model of coronary spasm.
Topics: Acetylcholine; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Choline | 2006 |
Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Defibrillators, Implantable; Disease Models, Animal; Dogs; Ele | 2007 |
[Effects of metoprolol on cardiac function and myocyte calcium regulatory protein expressions in rabbits with experimental heart failure].
Topics: Animals; Aortic Valve Insufficiency; Calcium; Calcium-Binding Proteins; Disease Models, Animal; Hear | 2007 |
Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiomyopathies; Dia | 2008 |
[Effect of chronic myocardial infarction on the distribution of beta-adrenoceptors in heart: experiment with dogs].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2007 |
Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Carbazo | 2008 |
Sex differences to myocardial ischemia and beta-adrenergic receptor blockade in conscious rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardia | 2008 |
Benefits of long-term beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2008 |
Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Disease Models, Animal; Heart Failure; | 2008 |
Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Brain; Disease Models, | 2008 |
Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; Cells, Cult | 2008 |
In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Area Under Curve; Disease | 2008 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disea | 1995 |
Effects of oral pretreatment with metoprolol on left ventricular wall motion, infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion.
Topics: Administration, Oral; Animals; Coronary Circulation; Coronary Thrombosis; Coronary Vessels; Disease | 1994 |
Possible isozyme-specific effects of experimental malaria infection with Plasmodium berghei on cytochrome P450 activity in rat liver microsomes.
Topics: Acetylation; Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; Isoenzymes; Malaria; M | 1994 |
Effects of metoprolol on left ventricular function in rats with myocardial infarction.
Topics: Animals; Blood Pressure; Coronary Vessels; Diastole; Disease Models, Animal; Dose-Response Relations | 1994 |
Early intravenous administration of metoprolol enhances myocardial salvage by thrombolysis with recombinant tissue-type plasminogen activator after thrombotic coronary artery occlusion in the dog by improvement of the collateral blood flow to the area at
Topics: Animals; Collateral Circulation; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Evaluation, | 1994 |
Effect of beta-blockade on left atrial contribution to ventricular filling in dogs with moderate heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Disease Models, Animal; Dogs; Echocardiog | 1996 |
Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Dogs | 1998 |
Angerlike behavioral state potentiates myocardial ischemia-induced T-wave alternans in canines.
Topics: Adrenergic beta-Antagonists; Anger; Animals; Arousal; Blood Pressure; Death, Sudden, Cardiac; Diseas | 2001 |
Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Carbazoles; Cardi | 2002 |
[Effects of kitchen salt and beta sympatholytics on the course of blood pressure in the hereditary, spontaneously hypertensive rat (SH rats, Münster strain)].
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Hypertension; Metoprol | 1977 |
Metoprolol and ventricular repolarisation and refractoriness: lack of chronic adaptational class III effects in rabbit.
Topics: Animals; Disease Models, Animal; Electrophysiology; Epinephrine; Heart; Isoproterenol; Male; Metopro | 1991 |
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Topics: Administration, Oral; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Melli | 1990 |
Inducible monomorphic sustained ventricular tachycardia in the conscious pig.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Heart Ventricles; Hemodynamics; Lidocaine; Ligati | 1990 |
Combination of ribose with calcium antagonist and beta-blocker treatment in closed-chest rats.
Topics: Adenine Nucleotides; Animals; Cardiac Output; Disease Models, Animal; Dose-Response Relationship, Dr | 1987 |
Atherosclerosis in rabbits identified as high and low responders to an atherogenic diet and the effect of treatment with a beta 1-blocker.
Topics: Animals; Aorta; Apolipoproteins; Arteriosclerosis; Cholesterol; Coronary Vessels; Diet, Atherogenic; | 1988 |